David A. Siegel Protagonist Therapeutics, Inc Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $3.52 Million - $4.95 Million	-104,500 Reduced 89.62%	12,100 $543,000
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $1.98 Million - $2.79 Million	-80,100 Reduced 40.72%	116,600 $4.04 Million
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $551,287 - $813,395	-25,300 Reduced 11.4%	196,700 $5.69 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $1.33 Million - $2.22 Million	-94,900 Reduced 29.95%	222,000 $5.09 Million
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $1.59 Million - $2.25 Million	-95,200 Reduced 23.1%	316,900 $5.29 Million
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $679,354 - $1.11 Million	-37,700 Reduced 8.38%	412,100 $11.4 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $1.66 Million - $3.9 Million	-153,700 Reduced 25.47%	449,800 $10.3 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $1.44 Million - $2.19 Million	196,200 Added 48.17%	603,500 $6.58 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $873,246 - $1.3 Million	-111,100 Reduced 21.43%	407,300 $3.43 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $873,246 - $1.3 Million	-111,100 Reduced 21.43%	407,300 $3.43 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $2.14 Million - $7.75 Million	303,700 Added 141.45%	518,400 $4.1 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $4.11 Million - $6.35 Million	175,900 Added 453.35%	214,700 $5.08 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $1.88 Million - $3.95 Million	-106,500 Reduced 73.3%	38,800 $1.33 Million
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $1.43 Million - $5.5 Million	-110,775 Reduced 43.26%	145,300 $2.58 Million
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $2.32 Million - $4.07 Million	-90,600 Reduced 26.13%	256,075 $11.5 Million
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $391,812 - $641,690	-20,600 Reduced 5.61%	346,675 $8.98 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $223,728 - $304,073	12,100 Added 3.41%	367,275 $7.4 Million
Q3 2020 Nov 16, 2020	SELL	$15.19 - $22.4 $972,539 - $1.43 Million	-64,025 Reduced 15.27%	355,175 $6.94 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $1.2 Million - $3.66 Million	194,500 Added 86.56%	419,200 $7.4 Million
Q1 2020 May 15, 2020	SELL	$5.4 - $9.22 $509,220 - $869,446	-94,300 Reduced 29.56%	224,700 $1.59 Million
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $782,292 - $2.24 Million	166,800 Added 109.59%	319,000 $2.25 Million
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $255,952 - $450,431	27,200 Added 21.76%	152,200 $1.83 Million
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $280,176 - $404,352	31,200 Added 33.26%	125,000 $1.51 Million
Q1 2019 May 15, 2019	SELL	$6.5 - $13.77 $15,600 - $33,048	-2,400 Reduced 2.49%	93,800 $1.18 Million
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $295,470 - $489,636	-46,900 Reduced 32.77%	96,200 $647,000
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $100,936 - $166,648	-14,800 Reduced 9.37%	143,100 $1.47 Million
Q2 2018 Aug 14, 2018	BUY	$5.99 - $9.1 $663,692 - $1.01 Million	110,800 Added 235.24%	157,900 $1.06 Million
Q1 2018 May 15, 2018	BUY	$8.46 - $23.08 $251,262 - $685,476	29,700 Added 170.69%	47,100 $405,000
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $251,778 - $361,920	17,400	17,400 $362,000

Others Institutions Holding PTGX

# of Institutions

304

Shares Held

61.3M

Call Options Held

1.01M

Put Options Held

555K

Farallon Capital Management LLC San Francisco, CA

6.11M
Shares

$344 Million
1.7% of portfolio
Black Rock Inc. New York, NY

5.76M
Shares

$324 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.72M
Shares

$322 Million
4.53% of portfolio
Vanguard Group Inc Valley Forge, PA

4.28M
Shares

$241 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

3M
Shares

$169 Million
5.07% of portfolio

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.76B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account